Chi-Med Starts China Phase II Trial of Surufatinib/Tuoyi Combo in Solid Tumors
publication date: Jan 14, 2020
Hutchison China MediTech (Chi-Med) has started a China Phase II trial of surufatinib in combination with Tuoyi, Shanghai Junshi Bio's approved PD-1 drug, in patients with advanced solid tumors. Surufatinib is an oral anti-angiogenesis VEGFR inhibitor that also inhibits colony stimulating factor-1 receptor (CSF-1R), promoting a macrophage immune response. In June 2019, Chi-Med stopped a Phase III test of surufatinib early because it met its progression-free survival endpoint in patients with neuroendocrine tumors. More details....
Stock Symbols: (AIM/NSDQ: HCM)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.